The SWOT of the company

Looking at the SWOT of the company reveals that the company is highly focused on its R&D and as it had been witnessed it has a few popular drugs on the market and it is heavily competing with others either to gain market share or to manufacture or to come up with popular products. The fact that it has a good number of drugs on it phase II and III level means even if the success rate is lukewarm in that area, where three out of ten products only might make it to the market, and the number of years that it will take is at around 15 years; since it is a standard in the industry its chance of competing with other is promising.
In addition, it is still acquiring new companies as it did recently when it had announced its plan to acquire Organon Bioscience. And among its strength are the fact that it is a diversified company that serves three different sectors, that will avail it three strong sectors with opportunities to excel in all them, which would give it an edge over the others that could be focused and heavily invested only on one sector. Which means its R&D covers a much wider sector availing it wider advantages. The fact that it has presence in more than 120 countries means its products are available for a large number of users and consumers.
Its patents for most of its products have not expired yet even if one of it popular drug Claritin had expired and it had replaced it with a generic drug, which would mean those who had seen good result in it will continue to use it keeping a good portion of its market share in its own hand. Its weakness might originate from without rather than from within and as long as it is other companies that are coming up with the innovative products it will continue to lag behind, which would mean it should attract top-notch workers in the field and whether through hard work or fluke it should come up with winning products. Also learn Gillette SWOT Analysis

The fact that it has three major sectors might make it difficult for it to excel in one sector a point that has merit and a demerit. If there are threats the competition for market share and for coming up with the winning products is not letting up and as the 17th player in the U. S. among the drug manufacturers it is going to be an uphill battle for the company both to stay in business, as well as to come up with winning products since the other well performing companies had a better chance of coming up with the right products.
And when that happens its role could be limited only in playing in the generic drug market that does not have an equivalent revenue as brand name products as they have much greater competitors. The other threat might be the access it will have in other emerging markets that are lucrative where it had shown some good success rate when one of its drug was approved in China, yet the lack of more winning products could also make it a lacklustre player in that sector too.
When it comes to opportunities it is not different than any of the drug companies except that since it has three lucrative sectors that are in high demand, as long as it can market the existing products effectively it could increase its market share by either keeping existing market or gaining new ground. It is also joining hands with other companies such Merck which will avail it more opportunities in markets others have gained ground, which means if it also comes with new products it would also bolsters its chance of gaining market shares.
The threats are none than what were touched up on where it has to go forward, it has to come up with new products as much as possible and it will have to market the existing ones aggressively not to lose market share. If it does not succeed in these two areas, not only its making profit but also its existence could be under threat, which means it has to beat the competition. As well it has also to adhere to the laws and rules of the nation since the drug industry is among the highly regulated industries in the country any deliberate deviation could be costly, as mistakes could easily be identified and be treated as such. [10]